BRPI0409936A - uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico - Google Patents

uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico

Info

Publication number
BRPI0409936A
BRPI0409936A BRPI0409936-2A BRPI0409936A BRPI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A
Authority
BR
Brazil
Prior art keywords
partially filled
filled container
medical kit
wall portion
coated glass
Prior art date
Application number
BRPI0409936-2A
Other languages
English (en)
Inventor
Michael Bech Jensen
Birthe Lykkegaard Hansen
Troels Kornfelt
Kirsten Kramer Jakobsen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34973305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2004/000181 external-priority patent/WO2004082708A2/en
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0409936A publication Critical patent/BRPI0409936A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00—Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)

Abstract

"USO DE UM MATERIAL, RECIPIENTE PELO MENOS PARCIALMENTE CHEIO, E, KIT MéDICO". Um material escolhido do grupo consistindo de: vidro revestido por sílica, vidro revestido por silicone, polímeros de olefinas não cíclicas, polímeros de ciclo-olefinas e copolímeros de ciclo olefina/olefina linear; é vantajoso como um material de parede interna, em um recipiente que é composto de (i) uma porção de parede e (ii) uma ou mais porções de fechamento que não constituem parte da porção da parede, e que contêm uma formulação de uma proteína tendo um dormínio amino-terminal de ácido <sym>-carboxiglutâmico (Gla) com 9-12 resíduos Gla.
BRPI0409936-2A 2003-05-23 2004-05-21 uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico BRPI0409936A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300788 2003-05-23
US47628003P 2003-06-05 2003-06-05
PCT/DK2004/000181 WO2004082708A2 (en) 2003-03-18 2004-03-18 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
PCT/DK2004/000359 WO2004103398A1 (en) 2003-05-23 2004-05-21 Protein stabilization in solution

Publications (1)

Publication Number Publication Date
BRPI0409936A true BRPI0409936A (pt) 2006-04-25

Family

ID=34973305

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409936-2A BRPI0409936A (pt) 2003-05-23 2004-05-21 uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico

Country Status (13)

Country Link
US (1) US8536127B2 (pt)
EP (1) EP1628677B1 (pt)
JP (2) JP5627832B2 (pt)
KR (1) KR20060015574A (pt)
CN (1) CN1780638B (pt)
AT (1) ATE454900T1 (pt)
AU (1) AU2004241698A1 (pt)
BR (1) BRPI0409936A (pt)
CA (1) CA2525224A1 (pt)
DE (1) DE602004025100D1 (pt)
MX (1) MXPA05012476A (pt)
RU (1) RU2364609C2 (pt)
WO (1) WO2004103398A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN104887620A (zh) * 2007-05-02 2015-09-09 诺沃—诺迪斯克保健股份有限公司 包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂
KR101140483B1 (ko) 2007-05-02 2012-07-11 에프. 호프만-라 로슈 아게 단백질을 안정화시키는 방법
EP2237038B1 (en) * 2007-10-22 2015-04-29 Becton Dickinson and Company Medical articles coated with organopolysiloxane containing a protein solution and non-ionic surfactant
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
WO2009143439A1 (en) * 2008-05-23 2009-11-26 Hospira, Inc. Packaged iron sucrose products
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
ES2897540T3 (es) * 2012-05-29 2022-03-01 Becton Dickinson France Revestimiento lubricante y dispositivo médico de inyección que comprende dicho revestimiento
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN107063940B (zh) 2016-02-10 2019-10-18 贝克顿迪金森法国公司 用于评价基于蛋白质的制剂的稳定性的方法
WO2018181531A1 (ja) 2017-03-29 2018-10-04 テルモ株式会社 プレフィルドシリンジ包装体
EP3760220B1 (en) 2018-02-28 2025-02-19 Seikagaku Corporation A package comprising lyophilized chondroitinase abc and method for manufacturing the same
CN114980851A (zh) * 2020-01-28 2022-08-30 日本瑞翁株式会社 预填充药剂包装和预填充药剂包装的制造方法
WO2024214811A1 (ja) * 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577070A (en) * 1897-02-16 Machines
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4404132A (en) * 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU593042B2 (en) 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
AU607927B2 (en) 1986-06-24 1991-03-21 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
CA2143125C (en) 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
EP0699075B1 (en) 1993-05-21 2001-12-12 Zymogenetics, Inc. MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SE9503679D0 (sv) 1995-10-20 1995-10-20 Pharmacia Ab Antioxidants
US5993795A (en) * 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5910138A (en) * 1996-05-13 1999-06-08 B. Braun Medical, Inc. Flexible medical container with selectively enlargeable compartments and method for making same
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
TR199901968T2 (xx) 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
DE19730023A1 (de) 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
JPH11335295A (ja) * 1998-05-22 1999-12-07 Towa Pharmaceutical Co Ltd カルシウム調節ポリペプチドホルモンの安定な非経口投与用水溶液製剤
DE19853033A1 (de) 1998-11-18 2000-05-25 Centeon Pharma Gmbh Stabilisierte Proteinzubereitung für einen Gewebekleber
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
GB9920772D0 (en) 1999-09-03 1999-11-03 Nycomed Amersham Plc Improved container composition for radiopharmaceutical agents
GB9920758D0 (en) * 1999-09-03 1999-11-03 Nycomed Amersham Plc Improved container composition for diagnostic agents
AU6875900A (en) * 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
US6750053B1 (en) * 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
DE50114021D1 (de) * 2001-01-08 2008-07-24 Csl Behring Gmbh Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
EP1232735A3 (en) 2001-02-20 2004-03-03 SCA Hygiene Products AB Diaper cover and method for manufacturing a diaper cover
US6858587B2 (en) * 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
AU2002351755A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе

Also Published As

Publication number Publication date
CN1780638A (zh) 2006-05-31
KR20060015574A (ko) 2006-02-17
JP2007502310A (ja) 2007-02-08
AU2004241698A1 (en) 2004-12-02
DE602004025100D1 (de) 2010-03-04
WO2004103398A1 (en) 2004-12-02
ATE454900T1 (de) 2010-01-15
CA2525224A1 (en) 2004-12-02
RU2364609C2 (ru) 2009-08-20
MXPA05012476A (es) 2006-02-22
RU2005140282A (ru) 2006-07-27
JP2012229230A (ja) 2012-11-22
EP1628677B1 (en) 2010-01-13
US20060160720A1 (en) 2006-07-20
EP1628677A1 (en) 2006-03-01
CN1780638B (zh) 2010-04-14
US8536127B2 (en) 2013-09-17
JP5627832B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
BRPI0409936A (pt) uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
WO2002020069A3 (en) Antioxidant enriched adhesive compositions and storage containers therefor
BRPI0607988A2 (pt) composto, composição farmacêutica, e método para induzir apoptose em uma célula
EP1315513A4 (en) CHEMICAL LIGATION &#34;PSEUDO&#34; -NATIVE
IL185142A0 (en) Lentiviral packaging constructs
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
TW200611910A (en) Interferon-alpha polypeptides and conjugates
BRPI0417721B8 (pt) kit contendo um medicamento farmacêutico, método para preparar uma formulação líquida de um fator recombinante viia, composição e métodos para preparar as composições
ES2122520T3 (es) Composicion de limpieza con dos partes que comprende al menos un compuesto de peroxido.
BR9407419A (pt) Implante de tecido mole aperfeiçoado
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
DK0625989T3 (da) DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer
EA200501692A1 (ru) Жидкие стабилизированные белковые составы в фармацевтических контейнерах с покрытием
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
DE69007662D1 (de) Verpackung zur Aufnahme und Mischung von zwei Komponenten.
BRPI0406652A (pt) Dispositivo refrescante de ar
GB0020080D0 (en) Injection moulding
AR033788A1 (es) Envase primario, uso de un tapon o embolo de caucho que contiene caucho de bromobutilo para sellar el envase primario y procedimiento para la manufactura del envase primario
DOP2001000279A (es) Uso de polimerizados como auxiliares de filtracion y/o estabilizantes.
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
SG158856A1 (en) Controlled release compositions based on block copolymers
ATE206075T1 (de) Isolierscheiben mit wax enthaltende thermoplastischen adsorptionszusammensetzungen
WO2004065410A3 (en) Mntf peptides and compositions and methods of use
ATE342205T1 (de) Flaschenträger

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.